

Manufacturing

Morten Jurs, CFO



Disclaimer:

THIS PRESENTATION HAS BEEN PREPARED BY PRONOVA BIOPHARMA ASA (THE "COMPANY") EXCLUSIVELY FOR INFORMATION PURPOSES. THIS PRESENTATION HAS NOT BEEN REVIEWED OR REGISTERED WITH ANY PUBLIC AUTHORITY OR STOCK EXCHANGE. THE DISTRIBUTION OF THIS PRESENTATION AND ANY OFFERING, SUBSCRIPTION, PURCHASE OR SALE OF SECURITIES ISSUED BY THE COMPANY IN CERTAIN JURISDICTIONS IS RESTRICTED BY LAW. POTENTIAL INVESTORS ARE REQUIRED BY THE COMPANY TO INFORM THEMSELVES ABOUT AND TO COMPLY WITH ALL APPLICABLE LAWS AND REGULATIONS IN FORCE IN ANY JURISDICTION IN WHICH IT INVESTS AND MUST OBTAIN ANY CONSENT, APPROVAL OR PERMISSION REQUIRED UNDER THE LAWS AND REGULATIONS IN FORCE IN SUCH JURISDICTION. THE COMPANY SHALL NOT HAVE ANY RESPONSIBILITY OR LIABILITY FOR THESE OBLIGATIONS. THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES IN ANY JURISDICTION TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH AN OFFER OR SOLICITATION IN SUCH JURISDICTION.



15 May, 2008

3

Key figures – Sandefjord site


- **Number of employees** **130**
 - *Production* 56
 - *QC* 26
 - *Maintenance* 16
 - *Process and Plant development* 9
 - *QA* 11
 - *HR, Finance and Administration* 12

- **Operation**
 - 24 – 7 – 365


Raw material sources

- **Crude fish oil rich in omega-3**
- **Mainly source Pacific Ocean (Peru, Chile)**
 - *Anchovies*
 - *Sardines*


Structure of fish oil trade



Production volumes 2007(918) / 2008 (estimated 1200)




Production capacity Sandefjord



Focus areas 2008


- **Six Sigma projects to increase yield and efficiency**
- **Continued focus on robust production processes**
- **Prepare and upgrade for 1 300 tonnes in 2009**
- **In-sourcing of intermediates from third party**

Production volumes to meet future demand




New capacity in Kalundborg to meet future demand

Expected investment profile



Estimated employee ramp-up



- Operational expenditure accelerated in 2008
- Capital expenditure according to plan
- Total investment prognosis remains at NOK 1.45 to 1.70 billion

Production of API

